Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 3 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| RAPT Therapeutics Inc | RAPT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.00 | 08:14:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 3 | - | 6.86 - 27.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:09:15 | 1 | $ 7.99 | USD |
RAPT Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 278.38M | 34.80M | - | 0 | -116.8M | -3.36 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
RAPT Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RAPT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.17 | 8.31 | 7.62 | 7.96 | 584,038 | -0.17 | -2.08% |
| 1 Month | 8.42 | 9.6536 | 7.62 | 8.51 | 823,022 | -0.42 | -4.99% |
| 3 Months | 25.17 | 27.35 | 6.86 | 9.71 | 1,427,107 | -17.17 | -68.22% |
| 6 Months | 11.52 | 27.35 | 6.86 | 12.07 | 894,876 | -3.52 | -30.56% |
| 1 Year | 19.69 | 27.35 | 6.86 | 13.84 | 599,575 | -11.69 | -59.37% |
| 3 Years | 21.425 | 43.26 | 6.86 | 21.74 | 477,020 | -13.43 | -62.66% |
| 5 Years | 12.25 | 51.2095 | 6.86 | 22.09 | 379,406 | -4.25 | -34.69% |
RAPT Therapeutics Description
| RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
